AI Generated
Jul 2, 2026, 10:29
Nisar Ahmed: The Evolution of Anticoagulation Therapy
Nisar Ahmed, Pharmacist at Zubair Pharmacy, shared a post on LinkedIn:
“70 years of warfarin vs the new generation.
Here’s why anticoagulation has changed forever.
Warfarin — blocks vitamin K clotting factors, needs constant INR monitoring, dozens of food and drug interactions.
Still irreplaceable for mechanical heart valves.
Apixaban (Eliquis) — directly inhibits Factor Xa, predictable, no monitoring, fewer interactions.
The landmark ARISTOTLE trial: 21% less stroke, 31% less major bleeding, 11% lower mortality vs warfarin in AF.
- Mechanical heart valve? Stick with warfarin – DOACs are contraindicated.
- Non-valvular AF or VTE? Apixaban is now the standard of care.
- Full breakdown in the infographic . “
Stay updated with Hemostasis Today.
-
Jul 2, 2026, 10:44Priya Sriskandarajah: Understanding Anemia of Chronic Disease in Clinical Practice
-
Jul 2, 2026, 10:42Flora Peyvandi: Germline-Targeting Vaccines for HIV
-
Jul 2, 2026, 09:24Paschalis Evangelidis: Presenting Real-World Evidence to Improve Outcomes in TMA at EHA 2026
-
Jul 2, 2026, 09:09Mihaela Cordeanu: Can D-dimer Help Diagnose Splanchnic Vein Thrombosis?
-
Jul 2, 2026, 09:00Abdelrahman Essam: Why Early Hemorrhage Control Is Critical in Pelvic Fractures
-
Jul 2, 2026, 08:40Megan Adediran: Raising Awareness of Haemophilia Risks During Circumcision
-
Jul 2, 2026, 08:29Jo Jerrome: DETECT-VTE Audit Calls for Greater Awareness of Elusive Blood Clot Symptoms
-
Jul 2, 2026, 00:53Michel Ducreux: Real-World Cohort of Radioembolisation of HCC with Portal Vein Thrombosis
-
Jul 2, 2026, 00:30Randall Schaefer: Statewide Strategies for Prehospital Blood Product Access